Health Care • Biotechnology: Pharmaceutical Preparations
$1.07 ▼ -0.12
(-10.46%)
MKT CAP: $137.9M • VOL: 1.07M
52W L $1 52W H $5
ROARABLE / RQD
E • 34/100
PIOTROSKI
1 / 9
NBP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $264.0M | $144.0M | $632.0K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$94.3M | -$51.4M | -$72.0M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$46.3M | -$22.2M | -$207.7M |
| EBITDA (Normalized) | -$94.3M | -$51.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | — | — | -$183.8M |
| Capital Expenditures (CapEx) | $7.0K | $48.0K | — |
| Free Cash Flow (FCF) | — | — | -$183.8M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -30.6% | — |
| Cash & Short-Term Equivalents | $210.6M | $68.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $230.9M | $201.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NBP.